INTRODUCTION
there are also indications for a receptor-mediated mechanism by which apoA-V could lower the serum concentration of triglyceride-rich lipoproteins. In this regard, apoA-V has been shown to interact with heparan sulfate proteoglycans (HSPG) and several lipoprotein receptors such as the LDL receptor (LDLR), the LDL receptor-related protein 1 (LRP1), the sorting protein-related receptor containing LDLR class A repeats (SorLA/LR11), and sortilin (20) (21) (22) (23) . Whereas the roles of LDLR, LRP1 and HSPG as key factors in lipoprotein metabolism are widely accepted, the function of Vps10p-domain family members SorLA/LR11 and sortilin in lipid homeostasis remains less well understood. Interestingly, both receptors share many lipoprotein-associated ligands with LDLR family members, and bind in particular apoE, apoA-V, LPL and the receptorassociated protein (RAP) (21-26). Activation of LPL by apoA-V requires the enzyme to be surface-bound and, therefore, a model that accounts for the role of SorLA/LR11 and sortilin in apoA-V stimulation of LPL has been recently proposed (27) . Other models have also been advanced to explain the function of apoA-V in mediating receptor-or HSPG-dependent liver uptake of triglyceride-rich particles (19) . Noteworthy, sortilin has been recently shown to play a role in liver VLDL secretion (reviewed in (27, 28) ). A third mechanism by which apoA-V may lower triglyceride levels is thought to depend on intracellular processes that reduce liver VLDL secretion, and which could be linked to sortilin activity (19) .
Herein, we report a thorough structural and functional analysis of three mutations found in the APOA5 gene of three patients studied because of severe hypertriglyceridemia without concomitant LPL, APOC2, or GPIHBP1 gene mutations: a 12-bp deletion, c.694_705delTCCCGGAAGCTC (p.(Ser232_Leu235)del), a c.757T>C missense mutation (p.Leu253Pro), and a 4-bp deletion, c.990_993delAACA, which results in the C-terminally truncated protein p.Asp332ValfsX4. Our results strongly suggest that the mutated residues are critical for apoA-V function in lipoprotein metabolism and, therefore, directly responsible for the hypertriglyceridemia found in the patients studied.
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MATERIALS AND METHODS
Patients and controls
Three unrelated Spanish patients with severe hypertriglyceridemia were studied for diagnostic purposes. DNA from 200 non-hyperlipidemic subjects living in Barcelona, Spain, was used as a control (41% were women; age range: 17 to 85 years). The Ethics Committee of the Hospital de la Santa Creu i Sant Pau reviewed and approved the study protocol, and all individuals provided their written informed consent.
Plasma lipids, lipoprotein and apolipoprotein analyses
Blood samples were collected after an overnight fast. Standard, commerciallyavailable assays adapted to a Hitachi 911 autoanalyzer (Roche Diagnostics GmbH, Mannheim, Germany) were used to determine plasma total cholesterol, triglycerides and HDL cholesterol. ApoA-V in serum was measured by ELISA as previously described (17) ; serum apoA-V levels in 40 normolipidemic individuals ranged from 24 to 406 µg/L with a mean of 157 µg/L.
Gene amplification and analysis
Genomic DNA was isolated from whole blood using the QIAamp DNA blood minikit (QIAGEN, Hilden, Germany). The entire coding region of the Further, all exons and exon-intron boundaries -but not the promoter regions-of the LPL, APOC2 and GPIHBP1 genes were also amplified and sequenced. APOE genotype was determined by PCR amplification and digestion with Cfo I as described previously (30) .
Human apoA-V cloning, expression and purification
The full-length sequence of mature human apoA-V (residues R24-P366) was cloned as a synthetic gene via nucleotide assembly; codons were optimized for expression in Escherichia coli while reducing the number and length of potential hairpin loops in the mRNA. The construct contains an N-terminal polyhistidine tag introduced to facilitate detection and purification of the recombinant protein, which is followed by a factor Xa cleavage site (Ile-Glu-Gly-Arg-Gly-Ala). Oligonucleotide synthesis and assembly, as well as cloning into the pET-3a vector (Novagen, Darmstadt, Germany), were performed at Entelechon GmbH (Regensburg, Germany;
http://www.entelechon.com/). The sequence of the synthetic gene is available upon request.
Plasmids encoding polyhistidine-tagged mature apoA-V or its variants (see below) were transformed into E. coli BL21(DE3)pLysS (Stratagene, La Jolla, CA, USA).
Cells were grown at 37°C in LB medium supplemented with 100 µg/mL ampicillin and 34 µg/mL chloramphenicol to an optical density of 0.6, and then induced to express the recombinant proteins for 6 h at 20°C by adding 800 µM IPTG. After centrifugation at 4,000g for 10 min, cells were lysed with B-PER® supplemented with 20 mM 2-mercaptoethanol (2-ME), 1 mM EDTA, 200 mM NaCl, 10 mM MgCl 2 , 10 mM imidazole, 200 µg/mL lysozyme, 100 units/mL DNase I and protease inhibitor cocktail (Sigma- 
Site-directed mutagenesis
All apoA-V mutants were generated using the QuikChange® Site-Directed
Mutagenesis Kit (Strategene); the primers used are given in Supplementary Table 1 .
For variant p.(Ser232_Leu235)del, we first generated an intermediate form in which the codons for residues R233 and K234 were deleted; the six nucleotides coding for residues S232 and L235 were then removed from this plasmid in a second mutagenesis step. Mutant p.Asp332ValfsX4 was generated by first inserting four thymidines after the G334-encoding triplet to generate a F335 codon followed by a TAA stop codon. This intermediate plasmid was then subjected to a second mutagenesis round to replace the wild-type D332-S333-G334 tripeptide by the mutant Val-Ala-Arg sequence.
SDS-PAGE and Western blotting
conjugate from Pierce (Rockford, IL, USA; 1:10,000 dilution). Blots were revealed with SuperSignal chemoluminescence system (Pierce) according to the manufacturer's instructions, and exposed to autoradiography films.
Limited proteolysis
Samples of recombinant apoA-V at 100 µg/mL in 50 mM sodium citrate, 150 mM NaCl, 0.75 mM EDTA, pH 3.0 were incubated with porcine gastric pepsin at 25°C for up to 3 h. Aliquots of the reaction were then removed and immediately mixed with
Laemmli sample buffer and heated at 95°C for 10 min . Samples were separated on 12% polyacrylamide SDS-Tris-Tricine gels and either stained with Coomassie Brilliant
Blue or electrophoretically transferred to PVDF membranes and probed with an antiHis antibody (see above). Alternatively, aliquots of recombinant apoA-V in 100 mM
Tris-HCl, 0.1% NP-40, pH 8.5 were incubated with sequencing-grade trypsin (100:1 ratio), and the reaction progress followed as previously mentioned.
Preparation of apoA-V-DMPC liposomes
Lipid-free apoA-V variants were complexed 1:10 w/w with dimyristoylphosphatidylcholine (DMPC) liposomes prepared by extrusion through an 0.2-µm PC filter using an Avanti Mini-Extruder and following the manufacturer's instructions (Avanti Polar Lipids, Alabaster, AL, USA) (23) . Samples were spun for 10 min at 15,000g to remove residual liposomes, and protein content was determined using a BCA protein assay kit (Pierce).
ApoA-V binding to liposomes
The affinity of wild-type apoA-V and its variants for immobilized liposomes was assessed by surface plasmon resonance (31) using a Biacore 300 system (GE Healthcare 
ApoA-V binding to heparin
The affinity of wild-type apoA-V and its variants for immobilized heparin was assessed by SPR. Streptavidin was first immobilized on CM5 sensor chips (Biacore) using the amine coupling kit and following the manufacturer's instructions. The amount of immobilized streptavidin varied between 3,500 -4,000 resonance units (RU). Next, 180-200 RU of biotinylated heparin (Sigma) was coupled to these streptavidin-coated sensor chips via the covalently bound streptavidin moiety. Analytes (apoA-V variants)
were injected at a flow rate of 30 µL/min, and sensorgrams were recorded and analyzed using BIAevaluation 4.1 software.
ApoA-V interaction with LRP1 clusters II and IV
Recombinant human apoA-V variants were biotinylated using the sulfhydrylreactive EZ-Link Biotin-BMCC (Thermo Scientific, Rockford, IL, USA) following the manufacturer's instructions. The maleimide reactive group of this compound selectively reacts with the single cysteine residue in the apoA-V primary sequence, C227. For biotinylation, proteins were previously dialyzed into PBS, pH 6.5, using 0. 
ApoA-V binding to sortilin and SorLA/LR11
Soluble receptors used for SPR were prepared and coupled to CM5 sensor chips as previously described (22, 23) , and functionality of immobilized receptors was confirmed with the well-known pan-ligand, RAP. Owing to the complex binding behavior of apoA-V and the inability to regenerate flow cells injected with the apolipoprotein, conventional kinetic studies cannot be performed in this system. Therefore, we used single-cycle kinetics, which has proved suitable for kinetic analysis when cell regeneration is not possible (34) . Further, considering that apoA-V is found in plasma only as a lipid-associated protein and to mimic triglyceride-rich lipoproteins, apoA-V incorporated into 0.2-µm DMPC liposomes was employed for these studies. 
In vitro hydrolysis of triolein liposomes by HSPG-bound LPL
A previously reported assay (35) 
Bioinformatics analysis
For automated modeling, the amino acid sequence of the mature human apoA-V was submitted to various modeling servers through the Protein Modeling Portal
RESULTS
Patients: clinical and family data, serum apoA-V levels and mutation analysis
Samples from three unrelated patients were referred (to F.B.-V.) for the molecular study of severe hypertriglyceridemia. None of them were overweight or suffered from diabetes mellitus and the only adult, patient 1, consumed almost negligible amounts of alcohol. Genetic analysis of patient 1 was requested after fibrate treatment failed to reduce the severe hypertriglyceridemia (see Table 1 In the three cases APOA5 mutations were found without concomitant mutations in the LPL, APOC2 or GPIHBP1 genes (see Table 1 for a summary of the main genetic data). None of the APOA5 mutations found in the patients were identified in 200 nonhyperlipidemic control individuals living in Barcelona, Spain. A common APOA5 polymorphism (rs3135506, p.Ser19Trp) repeatedly linked to hypertriglyceridemia (3, 10, 11, 37) was found in heterozygosis in patient 1, being present in the wild-type allele. Neither this nor another common APOA5 polymorphisms previously linked to hypertriglyceridemia (rs651821) were present in the other patients studied.
Cloning, expression and characterization of recombinant human apoA-V
To experimentally determine the underlying molecular defect(s) leading to hypertriglyceridemia in our patients, we overexpressed full-length, mature human apoA-V as well as the three novel apoA-V mutants detected (p.(Ser232_Leu235)del, p.Leu253Pro, and p.Asp332ValfsX4). Both wild-type, recombinant human apoA-V and the three mutants were straightforwardly purified by metal affinity chromatography ( Supplementary Fig. 3 ). Their identities were verified by Western blot and mass spectrometry analysis of trypsin digests (Supplementary Table 2 ).
For the envisioned functional studies, it was critical to employ properly folded proteins. Of note, most of the recombinant human apoA-V was recovered from the cytosolic, soluble fraction of E. coli cultures ( Supplementary Fig. 3 ), which strongly suggests that it was correctly folded. However, and to verify this point while avoiding protein aggregation, we subjected wild-type apoA-V to limited proteolysis with pepsin at acidic pH, similar to a recent report (see Materials and Methods and (Wong, 2008 #39)). As shown in Supplementary Fig. 4A , the recombinant protein was rapidly cleaved to generate a transient ≈30-kDa fragment, which was converted into a stable ≈20-kDa form after 30 minutes incubation with the protease. Importantly, this fragment appeared to be fully resistant to further pepsinolysis for at least three hours. The preferential cleavage of just two scissile peptide bonds out of the 74 sites predicted for a fully unfolded protein (http://web.expasy.org/peptide_cutter/) and generation of a stable "core" fragment of apoA-V strongly suggest that the recombinant protein was properly folded. Similar results were obtained when apoA-V samples were treated with trypsin at basic pH, in the presence of detergent NP-40 added to guarantee solubility at this pH value (Supplementary Fig. 4B ).
During the overexpression experiments of mutant p.Leu253Pro, the presence of a major degradation form with an apparent M r ≈33 kDa was repeatedly observed ( Supplementary Fig. 3 , lanes 5 and 6). This truncated form was not observed when either wild-type apoA-V or the other two mutants were expressed, and presumably resulted from the action of an endogenous proteinase(s). Of note, an apparently more radical protein modification such as truncation of the last C-terminal residues in mutant p.Asp332ValfsX4 did not enhance protease sensitivity ( Supplementary Fig. 3 , lanes 7 and 8). To verify that the introduced mutations did not result in an overall destabilization of the protein structure, limited proteolysis experiments were performed with the purified mutant proteins, as described above for wild-type apoA-V. In all three cases, a similar cleavage pattern was observed, characterized by the formation of a In comparison to other studied variants, a significantly lower affinity was detected for the mutant p.Leu253Pro, mainly caused by a relatively fast dissociation from the immobilized liposomes ( Fig. 1D and Table 2 ).
Mutants p.(Ser232_Leu235)del and p.Asp332ValfsX4 show impaired binding to immobilized heparin
Next, and considering that HSPG has been reported to be a bona fide apoA-V receptor, we compared the affinity of wild-type apoA-V and the mutants to immobilized heparin via SPR. Although all apoA-V variants interacted with streptavidin-bound biotinylated heparin, their kinetic parameters varied considerably; wild-type apoA-V and the point mutant p.Leu253Pro bound to heparin with similar affinity, while the deletion mutants p.(Ser232_Leu235)del and p.Asp332ValfsX4 had somewhat lower affinity (Fig. 2) . This difference was mainly due to slower association, as the dissociation rate constants of the proteins were of the same order of magnitude.
ApoA-V interaction with LRP1 clusters II and IV
ApoA-V is known to be internalized via classical lipoprotein receptors of the LDLR family, including LRP1 and SorLA/LR11 (22) . To test whether the identified apoA-V mutants could be compromised in terms of receptor binding and internalization, and to define interacting domains within LRP1, we analyzed the capacity of the recombinant variants to bind two major functional units of the receptor, termed clusters II (residues V and the three mutants bound to membrane-immobilized LRP1 cluster II to an apparently similar extent when adjusted for apoA-V concentration (Fig. 3) . By contrast, no interaction with wild-type apoA-V or the mutant apoA-V forms was observed when the cluster IV of LRP1 was used instead (data not shown). show any appreciable interaction with sortilin (Fig. 4D) .
Defective sortilin and
Finally, we analyzed apoA-V interactions with another multifunctional endocytic receptor, SorLA/LR11. As demonstrated above for sortilin, wild-type apoA-V bound tightly to the immobilized receptor (Fig. 5A) , while mutant p.Leu253Pro was found to be devoid of SorLA/LR11-binding ability (Fig. 5D) . Interestingly, mutant p.(Ser232_Leu235)del also displayed a complete SorLA/LR11 binding deficiency ( 
ApoA-V stimulation of LPL activity
As mentioned previously, current evidence supports the view that apoA-V affects plasma triglyceride levels at least partly through LPL activity stimulation. To verify whether some of the apoA-V mutants could differ in the extent of LPL stimulation, we analyzed the impact of wild-type and mutant apoA-V forms on the activity of HSPGbound LPL. The fold changes relative to LPL alone were as follows: wild-type apoA-V, A three-dimensional model for human apoA-V can be generated based on its homology to apoA-I
The results of limited proteolysis experiments performed by us and others (see above and ref. (38)) suggested a domain organization for lipid-free apoA-V analogous to that previously determined for apoA-I (39) and apoE (40) . Thus, in the absence of lipids, apoA-V would be expected to feature an elongated, four-helix bundle comprising N-terminal residues R24 to about L198, followed by a loosely attached double-helical segment (residues H205 to about A260) (Fig. 7A) . Finally, the C-terminal stretch up to P366 appears to be essentially disordered in the absence of lipids, but quickly adopts a helical conformation upon phospholipid binding (41) . The significant sequence similarity between human apoA-I and apoA-V ( Supplementary Fig. 1 ), suggested the crystal structure of the former as an appropriate template for developing a three-dimensional (3D) model of the N-terminal residues R24-A260 of human apoA-V via homology modeling. Indeed, about 100 of these residues are identical or physicochemically similar in the two apolipoproteins.
However, closer inspection revealed that most of the apoA-I residues that form an almost continuous aromatic core for its N-terminal four-helix bundle (e.g., Y29, F33, Fig. 1 ). Therefore, and to generate unbiased models of human apoA-V, we submitted the sequence of the mature apolipoprotein to various independent modeling servers. In line with the sequence similarity discussed above, one of the top models generated by I-TASSER closely followed the apoA-I architecture for helices A-F (Fig. 7B ). In addition, this model featured two C-terminal α-helices that could not be modeled based on the apoA-I template. In particular, the predicted Cterminal helix H comprises residues P326 to H360, fully in line with available experimental data (41) and secondary structure predictions. Models yielded by other servers also featured all α-helical bundles that could be partially superimposed on the apoA-I-derived model.
DISCUSSION
We report an in-depth analysis of three unrelated Spanish patients who presented severe hypertriglyceridemia. Since no mutations were found in the coding regions of their LPL, APOC2 or GPIHBP1 genes, we turned our attention to another gene, APOA5, that has been associated with this condition since its discovery (15 (7, 8) . On the other hand, current genetic and clinical information suggests that cases 2 and 3 suffer from familial hyperchylomicronemia, as the patients were children with mutations in both alleles of the APOA5 gene (homozygous p.Leu253Pro mutation and p.Gln97X / p.Asp332ValfsX4 mutations, respectively). Patient 3, however, showed high serum cholesterol levels, which is unusual in familial hyperchylomicronemia. It is currently unknown whether this is due to increased remnant lipoproteins and could relate to the presence of an APOE2 allele in the setting of a severe hypertriglyceridemia. To the best of our knowledge only one case of familial hyperchylomicronemia due to an APOA5 homozygous mutation had been described before (7).
The molecular mechanisms that result in severe hypertriglyceridemia in patients with APOA5 mutations remain poorly understood, and only one study to date has addressed the capacity of apoA-V mutants to interact with LDLR family members and activate LPL (42) . In addition, a recent report focused on the role of residue G185 in apoA-V-mediated LPL stimulation (43) . Therefore, we performed functional analyses of the three novel APOA5 mutations that do not have an obvious impact on apoA-V function. The results of these studies are summarized in Table 3 and discussed below.
First, we notice that apoA-V was detected by ELISA in the serum of all three patients. In fact, the serum apoA-V concentrations of patients 1 and 2 would be at the 95 th percentile and in the mean of a normolipidemic control group, respectively. In line with these findings, similar amounts of both wild-type apoA-V and all three mutants could be produced as properly folded proteins by recombinant expression in E. coli cells. A lack of correlation between serum apoA-V and triglyceride levels in patients with hypertriglyceridemia without extreme apoA-V deficiency has been previously described and discussed (19, 44, 45) . Possibly, the excess of serum triglyceride-rich particles compensates for a decrease in the synthesis or secretion of apoA-V, provided the mutation does not cause an extreme protein deficiency.
While our study was in progress, mutant p.Leu253Pro was found in heterozygosis in an Italian patient with severe hypertriglyceridemia (46). We did not find this mutation in 200 Spanish control individuals; neither was it found in 350 subjects randomly selected from an Italian population (46) . It is thus likely that this APOA5 mutation is causally linked to the observed phenotype, especially considering that residue L253 is strictly conserved from amphibians to humans. In fact, this apparently less deleterious point mutation, compared to both the internal (p.(Ser232_Leu235)del) and C-terminal deletions (p.Asp332ValfsX4), presented the most notable molecular defects, including higher sensitivity to proteolysis and impaired interactions with immobilized liposomes. Further, the p.Leu253Pro mutant was fully defective in terms of sortilin and SorLA/LR11binding, and failed to stimulate LPL activity. In contrast, this variant retains the capacity to interact with LRP1 cluster II, and binds to heparin with similar affinity as the wild-type protein.
In line with the strict conservation of L253, PolyPhen classifies the Leu253→Pro mutation as "probably damaging", and SIFT as "not tolerated". For comparison, the apoA-V polymorphism p.Ala315Val, which is associated with normal plasma TG levels (47) , is classified as "benign" or "tolerated". I-Mutant2.0 also predicts decreased stability for this mutant (∆∆G = -0.67 kcal/mol), in contrast to an increase of almost the same magnitude for the p.Ala315Val variant. Residue L253 is essentially buried at the interface between helices E and F in the 3D model of human apoA-V (Fig. 7C) .
Therefore, its replacement by a proline would have a double impact on the protein structure: loss of hydrogen bond interactions to residue L250 and perhaps also L257, and creation of a small cavity at this interface. Considering similar structural rearrangements for apoA-V such as those well-documented for apoA-I (39, (48) (49) (50) (51) , it is conceivable that local unfolding around position 253 leads to the sequential 'melting' of helices F and E, which perhaps propagates to the downstream helices. In line with these qualitative considerations and based on the homology model, CUPSAT predicted the Leu253→Pro replacement to be both unfavorable and destabilizing, with a ∆∆G value of -0.69 kcal/mol, while PoPMuSiC also classified the mutation as destabilizing, due to an even larger drop in free energy. It is interesting to note that the nearby, also strictly conserved L242 was found replaced by a proline in a hyperchylomicronemic proband; however, its causal involvement in the disease was not established (52). In the light of our current findings, it is likely that also in this case the disease phenotype was directly related to the APOA5 point mutation. Conceivably, these non-conservative leucine-to-proline replacements would affect the protein structure in the lipid-free / lipidpoor conformation, resulting in a higher susceptibility to proteolysis. On the other hand, the absence of these hydrophobic side chains would compromise phospholipid binding, as demonstrated here for the p.Leu253Pro variant.
The effects of apoA-V mutants on LPL activation appear to be highly variable depending on the affected residue (7, 8, 42, 43) . However, it is noteworthy that variant p.Leu253Pro not only did not activate LPL but rather inhibited the enzyme activity almost completely, a result not observed so far with other recombinantly generated apoA-V mutants (42, 43) . This observation clearly points to a direct or indirect effect of With the exception of R233, the four residues deleted in the novel apoA-V mutant p.(Ser232_Leu235)del are strictly conserved from amphibians to humans, and the S232-L235 tetrapeptide is within or close to a region implicated in the binding of lipids, heparin and receptors (e.g., GPIHBP1), and also important for LPL activation (19, 21, 56) . The recombinant mutant protein showed increased affinity for liposomes but decreased binding to heparin and sortilin, and did not bind to immobilized SorLA/LR11.
By contrast, it interacted with LRP1 cluster II, and retained the capacity to activate LPL.
The impaired interaction with heparin is not surprising, as this mutation eliminates a pair of consecutive positively charged residues (R233 and K234). In addition to this loss of net positive charge, the 4-residue deletion would alter the distance between Nand C-terminal basic residues within this putative HSPG-binding epitope (e.g. R211 / R223, on the one hand, and R245 / R254 on the other). The combined effect of a lower net charge and the disrupted location of the remaining basic residues would compromise specific protein-proteoglycan interactions. These findings are in line with the previously reported decrease in heparin affinity by mutant p.(Arg233Glu, Lys234Gln) (23) . Even more dramatic consequences might be expected for the binding to the N-terminal, highly acidic peptide of GPIHBP1, as indicated by an apoA-V mutant in which residues R233, K234, K238 and K240 were simultaneously replaced by glutamic acid or glutamine residues (56-58).
Inspection of the 3D model suggests deletion of the loop between helices E and F as a further plausible explanation for the deleterious effect of this mutation (Fig. 7B,   D ). This would likely result in an aberrantly long α-helix that spans residues from around V213 to S258, in turn drastically changing the position of the C-terminal region of mutant apoA-V relative to the N-terminal four-helix bundle. Further, hydrophobic residues that are protected from bulk solvent in wild-type apoA-V (mostly leucines, such as L213, L240, L253, and L257) would then form an exposed hydrophobic patch, thereby explaining the higher affinity for liposomes measured in the current work.
Finally, the novel apoA-V mutant p.Asp332ValfsX4 lacks the last 32 C-terminal residues of the protein, which are particularly well conserved in mammals ( Supplementary Fig. 1 ). Compared with wild-type apoA-V, this variant bound more tightly to liposomes, but showed impaired interactions with heparin, sortilin, and SorLA/LR11. On the other hand, this mutant showed no detectable changes in the capacity to bind LRP1 cluster II or to activate LPL. The C-terminal region of apoA-V (residues 296-343) has been previously shown to modulate its lipid-binding activity (19, 59) . The apparent contradiction with our current results suggests that residues 296-334 play a particularly significant role in this regard.
Both free and DMPC-complexed apoA-V bind LRP1, SorLA/LR11 and sortilin (22) and impaired binding to LDLR family members might lead to hypertriglyceridemia (42) . Somewhat unexpectedly in the light of these findings, the three apoA-V mutants were shown to bind to LRP1 cluster II. Even though apoA-V-LRP1 interactions were studied qualitatively, it is unlikely that major changes in receptor affinity could have gone undetected with our ligand blot assay. Along these lines, in similar experiments the human apoA-V mutants p.(Gln139-Leu147)del, p.Gly185Cys, p.Glu255Gly, and p.His321Leu bound normally to the chicken LDLR family member, LR8, while neither the N-terminally truncated apoA-V mutants, p.Gln139X and p.Gln148X, nor a variant prone to multimerization, p.Gly271Cys, were able to bind the avian receptor (42) . On the other hand, the pair of basic residues R233/K234 contributes to LRP1 binding, as the double mutant R233E/K234Q showed a three-fold lower affinity than wild-type apoA-V for the full-length human receptor (23) . Altogether, these results suggest that the major LRP1 binding region in apoA-V is located within helices C-D along with the following helix pair, but with little or no contribution from the N-or C-terminal portions of the protein, and in particular from the last C-terminal residues, D332-P366. This binding mode would thus be somewhat similar to the interaction of the related apoE with LDLR (60, 61) .
In striking contrast to the retained LRP1-binding ability, the interactions of all three apoA-V variants with sortilin and SorLA/LR11were impaired to different degrees.
The crystal structure of the sortilin ectodomain bound to neurotensin reveals a β-
propeller module that accommodates the C-terminal residues of the neuropeptide within a deep internal cavity, which contains additional ligand binding sites (62) . On the other hand, C-terminal moieties from other fully unrelated sortilin ligands such as LPL (25), RAP (63), prosaposin (64) and progranulin (65) are critical for receptor binding. In the light of these findings, it is not surprising that the C-terminally truncated apoA-V variant, p.Asp332ValfsX4, binds poorly to SorLA, and also showed reduced affinity for sortilin. The observation that mutant p.Leu253Pro did not interact with these receptors is more unexpected, and might be explained by an overall collapse of the C-terminal apoA-V region elicited by this point mutation, as discussed above. Our findings reinforce the notion that sortilin and SorLA/LR11 employ different (sub)domains and mechanisms of action for binding the same ligand, as previously shown for LPL (25, 66) . In this regard, it must be recalled that, in addition to the common Vps10p domain, SorLA/LR11 contains LA repeats similar to those found in other members of the LDLR family. These ligand binding domains share many ligands with each other, and our current data support the presence of a partly overlapping binding domain in apoA-V, as previously suggested (22) . Finally, it is worth noting that both sortilin and SorLA have been shown to facilitate endocytosis of apoA-V-DMPC disks. As SorLA, in contrast to apoA-V, is not primarily expressed in the liver, it is likely that the receptor participates in endocytic functions involving apoA-V rather than its intracellular processing. Sortilin, on the other hand, is abundantly expressed in the liver and further studies are needed to ascertain whether apoA-V plays a role in VLDL secretion, as recently suggested (67) .
In summary, our study strongly suggests a causal relationship between three novel APOA5 mutations and the hypertriglyceridemia found in the patients through Notice that the side chain of residue R233 is clamped between the carboxylates of two well-conserved acidic residues donated by helix G, E308 and E309. In panels (C) and (D), selected residues are shown as color-coded Van-der-Waals spheres. *** Not determined in the initial study. In a later determination, serum apoA-V concentration was 535 µg/L, while her plasma triglyceride levels had dropped to about 25% of the initial value. 
